Affilin -Precision Targeting Technology
Navigo Proteins’ Precision Targeting unit leverages its protein engineering expertise to create proprietary Affilin® molecules, harnessed to create optimized, next generation biopharmaceutical drugs in numerous fields of use. Navigo Proteins’ Affilin® platform benefits from the inherent engineerability, stability, safety, and ease of manufacturability. Our Precision Targeting unit comprises a versatile toolbox to custom-build selective biotherapeutic drug candidates, tailored in a flexible, modular fashion, to combine optimized selectivity, effector functions, and adjustable serum half-life. Currently, our Affilin® molecules are being developed as protein-drug conjugates (alternatives to antibody-drug-conjugates, ADCs). Other developmental areas include Affilin® molecules as CAR-T ligands, multi-specific affinity ligands, including bispecific antibodies, radiotherapeutics, or theranostics concepts
Navigo’s Affilin® molecules are based on human Ubiquitin which satisfies all the pre-requisites of an ideal scaffold-protein for designing next generation biotherapeutics.
- Ubiquitin is a natural protein of human origin (non-immunogenic).
- It is small (76 amino acids, 8.5kDa), stable, and highly engineerable.
- It is amenable to create large libraries of different Affilin® variants that bind the target of choice.